Previous close | 214.65 |
Open | 213.76 |
Bid | 218.02 x 800 |
Ask | 218.99 x 800 |
Day's range | 212.22 - 218.60 |
52-week range | 200.32 - 280.72 |
Volume | |
Avg. volume | 623,054 |
Market cap | 19.329B |
Beta (5Y monthly) | 1.06 |
PE ratio (TTM) | 15.53 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (1.32%) |
Ex-dividend date | 22 Feb 2023 |
1y target est | N/A |
BOSTON, February 22, 2023--Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app, which will now allow women to track menopause symptoms and access valuable resources and support to address the transition to menopause/perimenopause. The technology is available through Ovia’s consumer application and enterprise offerings for employers and health plans.
BURLINGTON, N.C., February 16, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance.
BURLINGTON, N.C., February 09, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea. Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services. With over 19,000 people, Fortrea will provide Phase I through IV clinical trial m